Navigation Links
Targeted Nanoparticles Offer Promise in the Battle Against Cancer
Date:10/16/2007

from a melanoma mouse model, in which 200 nm PRINT particles with aVb3 ligands successfully targeted the angiogenic tumor vasculature. Based on further pre-clinical studies, a PRINT-based cancer therapeutic is expected to enter clinical trials in 2008.

About Liquidia

Liquidia Technologies Inc. is an innovative nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Liquidia's proprietary PRINT(TM) platform is unique in its ability to replicate and produce nanoscale features with absolute control over particle size, shape, and composition. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. For additional information, please visit http://www.liquidia.com.


'/>"/>
SOURCE Liquidia Technologies
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
9. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)..., MEMPHIS, Tenn., Jan. 7 /PRNewswire-USNewswire...e that predict a high likelihood of relapse in chi...hough the researchers caution that further researc...called IKZF1 or IKAROS, lead to leukemia relap...or future diagnostic tests to assess the risk of t...
(Date:1/7/2009)..., OXFORD, England, January 7 /PRNewswire/ -...mpany focused on allergy and critical care, today,...lts achieved in 2008 with,its ToleroMune(R) anti-...,patient recruitment for a further phase II clinic...rway in Canada, has recruited 120 patients with co...
(Date:1/6/2009)..., ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire...tical company focused on diseases of epidemic pote...andidate for the treatment of tuberculosis (TB), w...ly awarded clinical program contract to Dynport Va... contract, awarded by the National Institute of Al...
(Date:1/5/2009)..., BETHESDA, Md., Jan. 5 /PRNewswire-FirstCa...rmaceutical company developing novel, proprietary,...ion and autoimmune diseases,provides an outlook ..., Micromet intends to provide an update on its...ng events: , -- April 12 to 16, 2009: Updat...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Childhood Obesity May Be Leveling Off 20322 1Childhood Obesity May Be Leveling Off 20322 2Childhood Obesity May Be Leveling Off 20322 31 small step for a lab science 1 green leap for mankind 20320 11 small step for a lab science 1 green leap for mankind 20320 2Berkeley Premium Nutraceuticals Pushes Forward 20318 1Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans 20316 1Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans 20316 2
...cal data on leading,drug-eluting stent portfolio, ... -- Boston,Scientific Corporation today announced ...ss announcements at the annual Paris,Course on Rev... 22,to 25 in Barcelona, Spain. , "We will be annou... and registries, adding to the knowledge base for ...
...y 15, 2007 - Synthetic Blood,International, Inc. (...tatistical analysis of its Phase IIa study with Ox... In line with preliminary,study results announced ...at the primary endpoint of increasing patients, ox.... Data also show a,decrease in patient glucose and...
Other Medicine Technology:Boston Scientific Announces Schedule for EuroPcr 2007 2Boston Scientific Announces Schedule for EuroPcr 2007 3Boston Scientific Announces Schedule for EuroPcr 2007 4Boston Scientific Announces Schedule for EuroPcr 2007 5Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3
(Date:1/8/2009)...sessment for heart risk may not be accurate in som...News) -- Two studies, from the United States and t... the long-established Framingham Risk Score in pre..., The Framingham score, based on findings of a de...allows doctors to assess risk on the basis of seve...
(Date:1/8/2009)...PRNewswire/ -- A study released this week showing ...rom multiple chronic diseases shines a much-needed...re system to one that focuses on primary and secon...cine, the leader in disease prevention. , , (...06/NETU129LOGO ) , , The study, conducted by ...
(Date:1/8/2009)... sitting on the surface of cancer cells are keys t...reating and stopping the spread of certain types o...e, breast, ovarian and lung, among others. Armed ...teway for Cancer Research, an Illinois-based phila...o, M.D., Ph.D., and her co-workers at the Moores C...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
...! New research released on Monday suggests that a ... healthy and prolongs life. These findings stem fr...e in nuns. "It's been known for years that patholo...ssion or hostility can lead to illness," said Davi...
... during clinical trials, may be the in thing in AI...e HIV from circulating blood, has been developed a... mark the beginning of the end of HIV’s vicious gr...rs at Aethlon Medical, a biotechnology firm in La ...
..., may opt for mastectomy over breast-conserving lu... gene mutation, researchers said California on Mon...sed by an inherited genetic susceptibility. The ma...utations or alterations in two genes, BRCA1 and BR...
... AIDS therapy, complimentary and alternative medic...e patients, according to a new study. Among 191 HI... complementary and alternative therapies, 67% said...t to control their HIV infection and 40% reported ...
Other Medicine News:
... modular external fixation system designed to acco...needs. Originally marketed in Europe under the Fix...y of clinical use in the global healthcare marketp...rov technique begun in Russia over 50 years ago, R...
...N AVIA tonometer is an easy-to-use, hand-held inst...trongly with Goldmann tonometry. TONO-PEN AVIA has...tronic measurement technology that enables operato... minimal training. TONO-PEN AVIA is powered by a l...
The QuickLink™ Delivery System is a cartridge based device designed to assemble brachytherapy seeds, spacers and SourceLink Connectors into seed trains of variable lengths and with variable seed
...ollection benefits from innovative research in mat...ectors such as the aerospace and automotive indust... and the footwear and textile industry. , ,This kn...Carrera sunglasses collection to create unique and...
Medicine Products: